ClinicalTrials.gg
RecruitingNCT01802034RENAL AIDUpdated Apr 4, 2025

Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)

An observational study in Kidney Diseases, Kidney Failure, Chronic and Diabetic Nephropathy, sponsored by The Rogosin Institute. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-04.

Sponsored by The Rogosin Institute · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-13

Among 416 studies in Kidney Diseases with a site in United States — 64 open to participants now, 93 under way, 15 of them phase 3. Kidney Diseases · United States.

Planned enrollment
16th of 93
2,000 · median 226
Started
2013
with 12 others
Observational
96 of 416
24 open now
Primary completion
2028-08
later than 62 of 91 live
Registered
168th of 416
by date

Among the 416 studies in Kidney Diseases with a site in United States, this one is the 16th largest by planned enrollment of the 93 observational ones that give a count, is one of 13 that started in 2013, is one of 96 observational ones, reaches primary completion later than 62 of the 91 other live ones, and was the 168th registered.

Kidney Diseases

970 studies on the registry are indexed under Kidney Diseases; 184 are open to participants now.

Browse Kidney Diseases studies →

Open to participants now

64 of the 416 studies in Kidney Diseases with a site in United States are open now. Recruiting first, the newest first:

59 more — sign in →

All 64 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 130 Kidney Diseases studies recruiting now, 76 (58%) set no upper age limit and 34 (26%) stop at 75 or younger; 26 take children under 18; 22 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Watch this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 416 studies in Kidney Diseases with a site in United States, or all of them as a file.
02

Study summary

A central goal of this data repository is to collect data from a large population of subjects with a variety of renal disease states. Cohorts will include subjects with diabetes, inflammatory/autoimmune and transplant related renal conditions. Additionally, the repository will have the capacity to store biospecimens and electronic data in control subjects without established renal disease. This initiative will provide an opportunity to compare data from various disease states and controls with the objective of determining clinical and biological factors that predict disease progression, response to therapy and identify discriminating noninvasive clinical and biological features that predict renal biopsy findings.

Read the detailed description

RENAL AID is designed as an inclusive data and tissue repository that is capable of linking demographic, clinical, laboratory, histology, genetic and radiographic data into one interconnected electronic data collection instrument. It is hypothesized that by linking these typically disconnected data components into a single electronic repository, RENAL AID will be capable of discovering relationships between these otherwise disparate data sets in order to ascertain previously unknown factors and associations that contribute to the progression of disease, the incidence of complications (including renal failure) and response to therapy. Further, certain patterns of inflammatory and/or immune mediators present in the serum, whole blood and urine of subjects with renal disease may be predictive of the underlying histopathology present in renal biopsy specimens. The potential correlation of non-invasive markers with underlying histopathology in subjects undergoing renal biopsy may afford the ability to make renal diagnoses non-invasively in the future.

RENAL AID will obtain and follow clinical data on large numbers of subjects from a variety of ethnic, social and economic backgrounds in the following three research subject groups:

  1. Native Biopsy Tissue Group: This group consists of subjects for which an expectant renal biopsy is undertaken based upon clinical necessity for whom surplus tissue is available. Subjects enrolled in this group will be evaluated every 3 months for the first year following biopsy, then annually thereafter. Research whole blood, serum and urine will be obtained at these visits.
  2. Native kidney, non-tissue group: This group consists of subjects who have undergone a renal biopsy without specimen storage in the RENAL AID biorepository and/or subjects who have diabetes and concurrent kidney disease in the absence of a renal biopsy. Subjects enrolled in this group will be evaluated annually. Research whole blood, serum and urine will be obtained at these visits.
  3. Allograft tissue group: This group consists of subjects that have undergone a renal transplant and require a transplant biopsy for either surveillance (termed protocol biopsy) or "for-cause" indications. By definition, "for-cause" biopsies are performed when an unexpected clinical event occurs that warrants transplant biopsy. Such events include acute graft dysfunction, progressive decline of transplant function, proteinuria and hematuria. Subjects in this group will be evaluated at the time of the transplant biopsy and research whole blood, serum and urine will be obtained at the visit.

Additionally, as RENAL AID is designed as both a biospecimen and data repository with the objective to conduct a wide variety of diverse research based upon the data and tissue collected, there will be research investigations for which control subjects are necessary. In anticipation of this requirement, RENAL AID will have the ability to record clinical, laboratory and histology data on control subjects in the same manner as for research subjects for those studies that obligate a control group and will have the ability to store bio-specimens and tissue in the same manner as for research subjects. In these circumstances, control subjects will be consented and RENAL AID will store electronic data and biopspecimens per protocol.

03

Conditions studied

  • Kidney Diseases
  • Kidney Failure, Chronic
  • Diabetic Nephropathy
  • Lupus Nephritis
  • Glomerulonephritis, IGA
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects will be recruited from The Rogosin Institute, NewYork Presbyterian Hospital and affiliated institutions.

Eligibility criteria

Key Inclusion Criteria:

All Groups:

  • Males or females
  • 18 years of age and older
  • Willing and able to provide

Native Tissue Group:

  • Require an initial kidney biopsy for medical necessity

Native Kidney, Non-tissue Group:

  • Previously had a kidney biopsy and the tissue is not stored in this biorepository; or
  • Have diabetes and kidney disease and have not had a kidney biopsy

Allograft Tissue Group:

  • Have undergone a renal transplant and require a transplant biopsy for either surveillance or "for-cause" indications.

Key Exclusion Criteria for all Groups:

  • Inability to provide informed consent.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,000 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Native, Renal Tissue Preservation Group

    Subjects who have a renal biopsy and the tissue is possessed and maintained by the RENAL AID repository.

  • Native, Non-tissue Preservation Group

    1. Subjects who have had a renal biopsy but the tissue is not held by RENAL AID repository; and/or 2. Subjects with diabetes and renal disease who have not had a renal biopsy.

  • Transplant Nephropathy Group

    Subjects who have had a renal transplant and require a transplant biopsy for either surveillance or "for-cause" indications.

06

What researchers measure

Primary outcomes

  1. Change in disease progression

    Time frame: Up to 10 years

07

Study locations

1 of 1 sites recruiting
  • The Rogosin Institute
    New York, New York 10021, United States
    Recruiting
    • Betty-Jane Sloan, M.A. · Contactbjsloan@nyp.org · 646-317-0701
    • Alan S Perlman, MD · Principal investigator
    • Nathaniel Berman, MD · Sub investigator
    • James M Chevalier, MD · Sub investigator
    • Choli Hartono, MD · Sub investigator
    • Surya V Seshan, MD · Sub investigator
    • Manikkam Suthanthiran, MD · Sub investigator
    • John CL Wang, MD · Sub investigator
    • Thomas S Parker, PhD · Sub investigator
    • Daniel M Levine, PhD · Sub investigator
    • David Serur, MD · Sub investigator
    • Jun Lee, MD · Sub investigator
    • Liu M Frank, MD · Sub investigator
    • Meredith J Aull, PharmD · Sub investigator
    • Nelson Chen, CRC · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2013, a primary completion of Aug 2028 and a completion of Aug 2028. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2013
First posted
Mar 1, 2013
Start
Feb 2013
Primary completionEst.
Aug 2028
CompletionEst.
Aug 2028
Last update
Apr 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01802034
Lead sponsor
The Rogosin Institute
Collaborators
New York Presbyterian Hospital, Weill Medical College of Cornell University
Responsible party
Sponsor
First posted
Mar 1, 2013
Start date
Feb 2013
Primary completion
Aug 2028 (estimated)
Completion
Aug 2028 (estimated)
Last update
Apr 4, 2025

Study contacts

Nelson Chen, M.A.
Contact
nec9039@nyp.org
646-317-0785
Alan Perlman, M.D.
Contact
alp9021@nyp.org
212-746-1580
Alan S Perlman, M.D.
principal investigator · The Rogosin Institute

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion